Lindsey Shapiro, PhD,  science writer—

A research team is conducting two projects to learn more about neurological problems, including cognitive impairment and stroke, in people with sickle cell disease (SCD). Led by Hyacinth I. Hyacinth, PhD, at the University of Cincinnati, the team will focus on how various anti-inflammatory medications might act to prevent…

Interfering with two newly identified proteins — NFIA and NFIX — involved both directly and indirectly in silencing fetal hemoglobin in red blood cells, could be a new therapeutic approach for sickle cell disease (SCD), according to researchers. Their hypothesis is that inhibiting the production or activity of these…

ARU-1801, Aruvant Sciences’ experimental gene therapy for sickle cell disease (SCD), led to the production of fetal hemoglobin in red blood cells and significantly lowered the number of vaso-occlusive crises (VOCs) in a group of five people with severe SCD, according to data from the ongoing Phase…